暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股期权个股详情
CRVS240517P2000
- 0.08
- -0.02-20.00%
延时15分钟行情收盘价 05/14 15:59 (美东)
0.09最高价0.01最低价
0.05今开0.10昨收30张成交量30张未平仓合约数2.00行权价114.00成交额227.43%隐含波动率-14.82%溢价2024/05/17到期日0.00内在价值100合约乘数2天距到期日0.08时间价值100合约规模美式期权类型-0.2433Delta0.6691Gamma30.13杠杆倍数-0.0256Theta0.0000Rho-7.33有效杠杆0.0006Vega
分时
- 5日
- 日K
新闻
2024 年有 13 只内幕买入的细价股
内幕人士花费100万美元购买Corvus Pharmicals的更多股份
快讯 | 美国证券交易委员会备案称，截至5月2日，史蒂芬·科恩持有Corvus Pharmicals Inc9.9％的被动股份
Corvus Pharmaceuticals | 10-Q：季度报表
根据美国证券交易委员会最近的一份文件，Corvus Pharmicals Insider购买了价值100万美元的股票
2024 年 5 月 6 日，董事、总裁兼首席执行官 Richard A Miller 以 1,000,000 美元的价格购买了 Corvus Pharmicals (CRVS) 577,634 股股票。在向美国证券交易委员会提交表格4后，米勒
快讯 | Corvus Pharmicals公布第一季度财务业绩后，该公司股价走低
评论
$Corvus Pharmaceuticals(CRVS.US$ Corvus Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Advisors LLC(11.1%),OrbiMed Capital GP V LLC(11.1%)
$Corvus Pharmaceuticals(CRVS.US$ Richard A Miller, Director, President and CEO, on May 06, 2024, executed a purchase for 577,634 shares in Corvus Pharmaceuticals (CRVS) for $1,000,000. Following the Form 4 filing with the SEC, Miller has control over a total of 2,067,753 shares of the company, with 577,634 shares held directly and 1,490,119 controlled indirectly.
4
4
$Corvus Pharmaceuticals(CRVS.US$ Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $8
2
$Corvus Pharmaceuticals(CRVS.US$ Reuters· 2 mins Corvus Pharmaceuticals - Issue and Sell to Investors in Registered Direct Offering Aggregate of 13.5 Mln Shares of Common Stock, Among Others
2
$Corvus Pharmaceuticals(CRVS.US$ Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024
Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024
Interim Data from Ciforadenant Phase 1b/2 Trial in Front Line Renal Cell Cancer Exceeds Predefin...
1
2
阅读更多